Transradial Angioplasty: do we need more proof to adopt it for good?

Original title: Influence of Arterial Access Site Selection on Outcomes in Primary Percutaneous Coronary Intervention. Are the Results of Randomized Trials Achievable in Clinical Practice? Reference: Mamas A. Mamas et al. J Am Coll Cardiol Intv 2013. Article in press.

Antithrombotic therapy has improved the prognosis of patients with acute ST-segment elevation myocardial infarction by reducing ischemic events. However, this reduction has been achieved at the expense of a greater bleeding risk. A significant part of this bleeding is related to the access site. 

This study included all patients undergoing PCI in the UK between 2006 and 2010. It analyzed a total of 46128 patients; the transfemoral access site was used in 28091 patients (60.9%) and the transradial access in 18037 patients (39.1%). In 2006 the transradial approach was used in 12.5% of procedures; by 2010, it had grown to 49.5% of procedures.

Patients who underwent transradial access PCI received glycoprotein IIb/IIIa and thrombus aspiration more frequently, while transfemoral access PCI patients saw more artery bypass graft, shock and balloon counterpulsation.

Mortality at a follow up of almost two years (13.6% vs 6.7%; p<0.0001) and mortality at 30 days (5.1% vs 6.7%; p<0.0001) were both significantly lower in the transradial access patients.

After a propensity score analysis to adjust all baseline characteristic differences, the transradial approach continued to show significantly lower mortality rates, less bleeding, less vascular complications and less MACCW events than the femoral access site. 

Conclusion:

This analysis of patients treated by primary percutaneous coronary intervention in the United Kingdom over a 5-year period has shown that the transradial approach is associated to lower mortality rates compared to the transfemoral approach.

 Editorial comment:

The transradial approach appears to be one of the greatest achievements in the history of cardiology. From a wider perspective, thrombolytics compared to placebo had reduced mortality in 25% of infarction patients. Afterwards, PCI compared to thrombolytics reduced mortality in approximately 40%. These reductions in mortality rates are of similar importance as the reduction rates achieved with transradial PCI that this study analyzed (29%) or as a recent meta analysis of randomized studies (48%).

SOLACI.ORG

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...